Loading…
BioMarin Pharmaceutical Inc. is projected to rise to $75.63 by 2027, a +28% move from its current price of $59.12. BMRN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $58.19 | $59.12 | $60.07 | 0.00% |
| Jul 14 | $57.81 | $59.12 | $60.46 | 0.00% |
| Jul 15 | $57.52 | $59.12 | $60.77 | 0.00% |
| Jul 16 | $57.28 | $59.12 | $61.03 | 0.00% |
| Jul 17 | $57.06 | $59.12 | $61.26 | +0.01% |
| Jul 18 | $56.87 | $59.12 | $61.46 | +0.01% |
| Jul 19 | $56.70 | $59.12 | $61.66 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $56.70 | $59.12 | $61.66 | +0.01% |
| Week 2 | $55.72 | $59.13 | $62.74 | +0.01% |
| Week 3 | $54.99 | $59.13 | $63.59 | +0.02% |
| Week 4 | $54.38 | $59.14 | $64.31 | +0.03% |
| Week 5 | $53.85 | $59.14 | $64.96 | +0.04% |
| Week 6 | $53.37 | $59.15 | $65.55 | +0.04% |
| Week 7 | $52.94 | $59.15 | $66.09 | +0.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioMarin Pharmaceutical Inc. is a biotechnology company that engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Its products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy.
It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A.
The company was incorporated in 1996 and is based in San Rafael, California.
BioMarin Pharmaceutical Inc. (BMRN) is currently priced at $59.12 and trades in the healthcare sector with a market capitalization of $11.43B, holding the 853rd rank by market cap.
The forecast landscape presents a path of rising price averages over the coming years, with the 2026 average value at $59.12 and a trajectory toward higher levels through 2030 ($97.68 avg), 2040 ($226.89 avg), and 2050 ($383.36 avg). These figures illustrate meaningful upside potential across the longer horizon.
Projected ROI evolves from 0 in 2026 to 65.2 by 2030 and to 548.4 by 2050, signaling a strong, long-term bullish tilt in the outlook while acknowledging the inherent uncertainty of market movements.
A major floor 16.0% below — a decisive break under it would weaken the trend.
The nearest floor, 10.8% below — buyers have tended to step in here.
Price is pressing into resistance (2.1% away) — a breakout level to watch.
A major ceiling 10.0% above — clearing it would confirm fresh momentum.
Key BMRN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BMRN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $59.60 | Sell | $59.36 | Sell |
| MA 10 | $58.87 | Buy | $58.81 | Buy |
| MA 20 | $57.39 | Buy | $57.79 | Buy |
| MA 50 | $55.31 | Buy | $56.43 | Buy |
| MA 100 | $56.34 | Buy | $56.17 | Buy |
| MA 200 | $55.87 | Buy | $56.90 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.53 | Neutral |
| Stoch RSI (14) | 39.53 | Neutral |
| CCI (20) | 77.14 | Neutral |
| Williams %R (14) | -27.64 | Info |
| MACD (12,26,9) | 0.17 | Buy |
| ROC (12) | 4.64 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 72.36 | Neutral |
| TRIX (15) | 0.29 | Buy |
| Awesome (5,34) | 3.18 | Buy |
| Ultimate (7,14,28) | 66.58 | Neutral |
| Momentum (10) | 1.77 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 60.21 | Sell |
| ADX (14) | 16.81 | Neutral |
| ATR (14) | 0.83 | Info |
The near-term technical picture is bullish, with sentiment coded as BULLISH. RSI14 is at 60, suggesting modest positive momentum.
The 50-day simple moving average is at $55.31 and the 200-day simple moving average is at $55.87, indicating a constructive trend relative to nearby averages. Support is identified at $52.74 and resistance at $60.35, framing the immediate trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $49.67 | $59.12 | $76.18 | 0% | Neutral | |
| $61.94 | $75.63 | $96.56 | +28% | Bullish | |
| $71.08 | $88.42 | $115.93 | +50% | Bullish | |
| $72.45 | $91.51 | $122.54 | +55% | Bullish | |
| $76.30 | $97.68 | $133.16 | +65% | Bullish | |
| $79.84 | $103.46 | $143.26 | +75% | Bullish | |
| $85.22 | $111.68 | $156.84 | +89% | Bullish | |
| $97.99 | $129.77 | $184.60 | +119% | Bullish | |
| $107.94 | $144.37 | $207.84 | +144% | Bullish | |
| $116.83 | $157.73 | $229.59 | +167% | Bullish | |
| $161.12 | $226.89 | $346.10 | +284% | Bullish | |
| $253.84 | $383.36 | $626.83 | +548% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $49.67 | $59.12 | $70.56 | +0.00% |
| August 2026 | $51.57 | $60.38 | $72.22 | +2.12% |
| September 2026 | $50.31 | $59.18 | $71.33 | -1.99% |
| October 2026 | $49.71 | $58.71 | $71.24 | -0.78% |
| November 2026 | $51.22 | $60.70 | $74.06 | +3.39% |
| December 2026 | $52.25 | $62.13 | $76.18 | +2.35% |
Click any year to see its month-by-month BMRN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BMRN to range from $49.67 to $76.18 through 2026. The $59.12 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The BMRN price prediction for 2027 points to an average of $75.63 (low $61.94, high $96.56) — a potential gain of +28% on today's $59.12. Buyers look set to stay in control over this stretch.
In 2028, BMRN is projected to trade between $71.08 and $115.93, averaging $88.42 — a potential gain of +50% from today's $59.12. That is up +17% on the projected 2027 average. Momentum favours further upside here.
BioMarin Pharmaceutical Inc.'s 2029 outlook centres on $91.51, within a $72.45 to $122.54 range. That is up +3% on the projected 2028 average. That marks a +55% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, BMRN could reach as high as $133.16, with a base case around $97.68 and support toward $76.30 — roughly +65% from $59.12. Momentum favours further upside here.
Expect BMRN to range from $79.84 to $143.26 through 2031. The $103.46 average target implies a +75% move from current prices. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The BMRN price prediction for 2032 points to an average of $111.68 (low $85.22, high $156.84) — a potential gain of +89% on today's $59.12. Momentum favours further upside here.
In 2033, BMRN is projected to trade between $97.99 and $184.60, averaging $129.77 — a potential gain of +119% from today's $59.12. That is up +16% on the projected 2032 average. Buyers look set to stay in control over this stretch.
BioMarin Pharmaceutical Inc.'s 2034 outlook centres on $144.37, within a $107.94 to $207.84 range. That is up +11% on the projected 2033 average. That marks a +144% change versus current levels. Momentum favours further upside here.
By 2035, BMRN could reach as high as $229.59, with a base case around $157.73 and support toward $116.83 — roughly +167% from $59.12. Buyers look set to stay in control over this stretch.
Expect BMRN to range from $161.12 to $346.10 through 2040. The $226.89 average target implies a +284% move from current prices. That is up +44% on the projected 2035 average. Momentum favours further upside here.
The BMRN price prediction for 2050 points to an average of $383.36 (low $253.84, high $626.83) — a potential gain of +548% on today's $59.12. Buyers look set to stay in control over this stretch.
Investing $1,000 in BMRN today (≈ 16.91475 BMRN) could be worth
$6,484.4
+$5,484.4 (+548%) by 2050 · US Dollar
Based on the average projected BMRN price of $383.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BMRNwould be worth at today's price.
$1,000 invested in BMRN on Jul 10, 2025 (≈ 17.00102 BMRN) would be worth
$1,005.1
+$5.1 (+0.5%) today · 1.01× · US Dollar
Based on a BMRN entry price of $58.82 vs. today's $59.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $58.99 | $1,002.2 | +0.2% |
| 1 month ago | $56.17 | $1,052.52 | +5.3% |
| 3 months ago | $54.53 | $1,084.17 | +8.4% |
| 6 months ago | $57.71 | $1,024.43 | +2.4% |
| 1 year ago | $58.82 | $1,005.1 | +0.5% |
| All time (5.0y) ago | $81.5 | $725.4 | -27.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BMRN forecast.
Our base-case forecast reaches $120.00 around 2033.
Implied market cap at $120.00: $23.19B
The multi-year forecast shows a clear upward trajectory in average prices, with 2030, 2040, and 2050 highlighted as milestones: 2030 avg $97.68; 2040 avg $226.89; 2050 avg $383.36. These targets reflect sustained upside potential across an extended horizon, supported by bullish sentiment in the later years.
ROI follows a similar upward arc: 2030 ROI 65.2; 2040 ROI 283.8; 2050 ROI 548.4, illustrating substantial long-term upside relative to today’s level. The outlook remains bullish across the forward years, but these figures are estimates and not guarantees, subject to market and company-specific developments.
Tap a question to reveal the answer.
The forecast shows 2030 Avg $97.68, with Min $76.30 and Max $133.16; ROI 65.2; sentiment BULLISH.
The forecast features bullish sentiment from 2027 onward, with rising Avg values and positive ROI through 2050 (e.g., 2027 Avg $75.63, ROI 27.9; 2030 Avg $97.68, ROI 65.2; 2040 Avg $226.89, ROI 283.8; 2050 Avg $383.36, ROI 548.4). These are estimates, not guarantees.
Yes. 2030 Avg is $97.68 and 2031 Avg is $103.46, which implies surpassing $100 on average by 2031.
Current price $59.12; Market cap $11.43B.
2040 Avg $226.89; Min $161.12; Max $346.10; ROI 283.8; sentiment BULLISH.
BioMarin Pharmaceutical Inc. Community Discussion
0Share your BioMarin Pharmaceutical Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.